A COMPARISON Oit SOME UI TEE Being

Total Page:16

File Type:pdf, Size:1020Kb

A COMPARISON Oit SOME UI TEE Being A COMPARISON OIt SOME UI TEE ERGOT ALKALOIDS. being a Thesis Presented for the Degree of Doctor of Medicine Edinburgh University by Adam Cairns White, ßß.B., Ch.B., Ph.D., Wellcome Physiological Research Laboratories, Langley Court, Beckenham, Kent. INS, September, 1939. Com-parison alLome FrEot Alkaloids. A- Section I. Contents. Introduction pp 1-8 General Toxic Symptoms in:- Monkey pp. 8 - 27 Fowl pp. 27 - 34 Canary pp. 34 - 36 Ct pp. 36a - 43 Rabbit pp. 43 - 44 Guinea Pig pp. 44 - 45 Mice pp. 45 - 55 Frog p) 55 Discussion of Toxic Symptoms pp. 55 - 60 Actions on Temperature Regulation in:- Mice pp. 60 - 76 Rabbit pp. 77 - 96 -1- The ergot alkaloids, other than those that are molecular compounds, fail into two groups, a laevorotatory physiologically active group, and a dextrorotatory group which is considerably less active. Smith and Timmis drew attention to this fact in their paper on isoergine and isolysergic acids (1). In Table l I have assembled the ergot alkaloids in descending order of the number of constituent carbon atoms, and given, where possible, their rotations in chloroform. The figures are obtained from the papers of Smith and Timmis (1) (2). The decomposition products, ergine and isoergine have also been included. -2- 200 Table 1. (« } 5461 Ergotoxine C35114105N5 -226e Ergotinine 035H4106N5 +446° 191 Ergotinine C35H4106N5 +513° Ergotamine C33H3505N5 -1810 Ergotaminine C33113505N5 +4500 Ergosine C30113705N5 -1930 Ergosinine C30H3705N5 +5220 Ergotnetrine C19x2302N3 - Ergometrinine C19i-12302N3 . +5200 isoErgine C16H170 N3 Ergine C10170 N3 +598° -3- Since the publications of Smith and Timis (1) (2), Stoll and Burckhardt (3) have reported the isolation of yet another large moleculed pair of alkaloids, ergocristine and ergocristinine C35H3905N5 (this is the same gross formula as they give for ergotoxine) for which they have rotations (el )p in chloroform of -186° and +365e respectively. Ergometrine and isoergine are too insoluble in chloroform to give a rotation figure but Smith and Timmis (1) give a series of figures for p aridine. (Table 2.) -4- Table 2 200 (a ) 5461 Ergorrletrine c19H2302N3 -16° Ergometrinine 02N3 +596o isoErgine C19H170 N3 +25° Ergine C10170 N3 +6350 Lysergic Acid C16H1602N2 +490 isoLysergic Acid C16H1602N2 +3650 -5- The rotations for ergometrine and ergometrinine in pyridine show analogous differences to those found for the alkaloids with the higher molecular weights in chloroform solution. Ergosine and ergosinine are two new alkaloids (2) (4), but they also (as will be shown in this communication) fall into line. The ergine and lysergic acid series, while showing considerable differences in rotation do not show quite such marked differences in physiological action as is the case with the alkaloids of higher molecular weights. It should be noted that ergine belongs to the ergotinine ergometrinine series whereas lysergic acid belongs to the ergotoxine ergometrine series. That this differentiation in the nomenclature has arisen is unfortunate but it was a consequence of the historical sequence of isolation of these substances by Smith and Timis (5) and Jacobs and Craig (6) respectively. These lists include all the alkaloids definitely characterised as pure substances, as well as the breakdown products of -6- the erg;ine, and lysergic acid series. Sensibarnin (7) and ergoclavin (8) have been excluded. These two have been .characterised by Stoll (9) as mixtures, sensibarain as an e::¡juimolecular mixture of ergotamine and ergotarninine and ergoclavin as a mixture whose components are still under investigation. In a later paper he further states that Kftssner's (8) ergoclavin is composed of a dextro- and laevo- rotatory fraction. Smith and Tiinmis (2) reported leucine to be one of the products of acid hydrolysis of ergosinine and also report analytical figures strongly suggesting ergoclavin is a mixture of ergosine and ergosinine. Jacobs and Craig (11) report the presence of leucine as a product of the acid hydrolysis of ergoclavin. Kftssner himself (12) has also recognised that his ergoclavin is a mixture of two alkaloids. Further evidence of the non -unity of ergoclavin has been brought forward by Kofler and Kofler (13) who conclude that ergoclavin may possibly consist of two compounds, one of ergosine and -7- ergosinine, the other of ergotamine and ergosinine. Stoll and Burckhardt's (3) first isolation of ergocristine was from a double compound found in the mother liquors of ergotoxine from Spanish and Portuguese ergots the other component of which was ergosinine. These authors remarked on the analogies of this compound with erg=,oclavin. A. Kofler (14) has now described and characterised at least fourteen such molecular addition compounds between ergot alkaloids of opposing rotations. Provided suitable conditions are obtainable the list of such possible compounds is not yet exhausted. (L. Kofler) (15). So far, no compounds have been described between different ergot alkaloids with similar rotation. Very little is known of the quantitative or qualitative pharmacology of these compounds, and it will require prolonged and accurate comparisons if any results of value are to be obtained. A number of the ergot alkaloid pairs have not so far been examined together, and it is the purpose of this paper to extend these comparisons as far as my material allows. -8- The comparison of the activities of the various alkaloids and their decomposition products will perhaps be simplified if instead of describing the action of each pair as a whole, the actions of all pairs on a given species or physiological system are described together. GENERAL TOXI C SYMP'rO NbS . ( a ) Symptoms in the iVionkey . ERGOSINE. The same type of monkey was used in all our experiments with the ergot alkaloids, namely, silenus rhesus. The highest dose of ergosine given to a monkey was 4 mg. intramuscularly. The earliest symptoms were, pallor of the face and ears, and the animal was obviously ill at ease. The pupil was slightly contracted. The hair was roughened and the animal appeared to maintain its balance with great difficulty. Then the pupils were found to be dilated and did not react to light. Respiration was rapid and now and then a purposeless stretching out of the hands was observed. -9- At other times it sat all huddled up and ground its teeth frequently. When the animal partly lost its balance, it recovered with a convulsive shiver; this might be accompanied by twitching of the wrists. When the eyelids were raised, the pupils were seen to be very dilated. The huddled up position was disturbed every now and then by twitching of the muscles of the forelimbs, giving rise to a beating type of movement (clonus) with the wrists flexed. Four hours later the animal was found slightly more awake, but when the head was kept erect for a short time it finally fell jerkily forward and downward into the huddled up position, accompanied by a few twitches of the forearms. half an hour later, on being given a lump of sugar it was observed that the animal held it more awkwardly than usual and was still very timid. At the end of six hours it had largely recovered. The next day the animal was found to be slightly jumpy and was scratching itself more than normally. An attempt was made to induce chronic ergosine poisoning in a monkey, and between the 16th November, 1936, -10- and the 8th January, 1937, a total of 45.5 mg. was injected intramuscularly, at first in daily doses of 0.5 mg. and then after about three weeks the dose was doubled. A week later the dose was increased to about 2 mg. No symptoms of chronic poisoning were observed during or after the experiment and our supply of the drug did not justify proceeding further to determine the effect of higher doses of ergosine. The animal was apparently able to destroy moderate amounts of the drug without showing any chronic sympi oms. Whether this was due to the gradual developing of a tolerance to the drug or entirely due to insufficient dosage could not be determined. The develop?ient of tolerance to some of the other ergot alkaloids has already been noticed in the literature. RGOSININE . With large doses (il mg.), on intracardiac injection, the animal immediately became unconscious, gave a few dyspnceic gasps, became limp, assuming no characteristic -11- attitude and then died. Smaller doses (2 mg.) showed a much slower effect, the animal became less sure footed, and its movements were slower. At the end of twenty minutes, the animal was sitting in a corner supporting its body with its forelimbs (c.f. Fig. 1. where 5 mgm. had been given); it seemed dazed. It got up onto its perch, and had a great struggle to keep its position. The movements, however, were much slower than usual. The gripping power of the hind limbs was also reduced. The animal seemed, as it were, half awake. It was able to make a sudden rapid movement, but was unable to maintain am attitude or steady level of activity, for instance, when sitting, in the corner, it lay half on the side of its rump using its forelimbs to support the upper part of its body, the head would then slowly fall down and then be jerked back into its original position, (recalling the movements of the head when the human subject nearly drops off to sleep while sitting in a chair) . Fast movements were distinctly clumsy. A very characteristic attitude the animal adopted in this state was -12- a sort of Landseer lion attitude. At times, too, purposeless slow movements of the forelimbs were observed. Figure 1 shows the stage of the effects of 5 mg. ergosinine intracardiac in one of the monkeys. -13- Figure 1. Fig. 1. Monkey No 7.
Recommended publications
  • Determination of Sex 43, Elm Park Gardens, THOSE Who Are Interested in the Heredity of Sex Chelsea, S.W.Lo
    APRIL 14, 1934 NATURE 579 sa was correctly computed in five minutes, 510 in genes outweigh the female and the result is the twenty seconds and 610 in seventy seconds. normal haplo-X male." Division was a slower process and 9 digits divided Thus, as my italics show, the experimental by 3 took times varying from two and a half to geneticist seems to agree with what Prof. MacBride seven and three quarters minutes. has expressed in more generally intelligible language ; Square roots of 6 digit numbers were extracted in not only in admitting the essential sameness of sex less than a minute while cube roots took longer. in all organisms but also in understanding the Curiously enough, the memorising of a number of function of proportion in its determination in some 27 digits was not done successfully, although he of them. Unanimity among the different branches of could repeat questions which had been put to him biology has therefore been reached after a long period and their answers after some days had elapsed, and of divergence, from entirely different data and, what would break off calculations in the middle to ask for is more, apparently unawares. Such an event, surely, milk or cigarettes, taking up the calculations again should not be allowed to pass without notice and where he had broken off. His methods of working without applause. The usual view that the chromo­ were not discovered, but he had obviously memorised some theory of sex determination criticised by the squares of two digit numbers, and less completely MacBride was a special hypothesis put forward by the products of two digit numbers.
    [Show full text]
  • Headshop Highs & Lows
    HeadshopHeadshop HighsHighs && LowsLows AA PresentationPresentation byby DrDr DesDes CorriganCorrigan HeadshopsHeadshops A.K.A.A.K.A. ““SmartSmart ShopsShops””,, ““HempHemp ShopsShops””,, ““HemporiaHemporia”” oror ““GrowshopsGrowshops”” RetailRetail oror OnlineOnline OutletsOutlets sellingselling PsychoactivePsychoactive Plants,Plants, ‘‘LegalLegal’’ && ““HerbalHerbal”” HighsHighs asas wellwell asas DrugDrug ParaphernaliaParaphernalia includingincluding CannabisCannabis growinggrowing equipment.equipment. Headshops supply Cannabis Paraphernalia HeadshopsHeadshops && SkunkSkunk--typetype (( HighHigh Strength)Strength) CannabisCannabis 1.1. SaleSale ofof SkunkSkunk--typetype seedsseeds 2.2. AdviceAdvice onon SinsemillaSinsemilla TechniqueTechnique 3.3. SaleSale ofof HydroponicsHydroponics && IntenseIntense LightingLighting .. CannabisCannabis PotencyPotency expressedexpressed asas %% THCTHC ContentContent ¾¾ IrelandIreland ¾¾ HerbHerb 6%6% HashHash 4%4% ¾¾ UKUK ¾¾ HerbHerb** 1212--18%18% HashHash 3.4%3.4% ¾¾ NetherlandsNetherlands ¾¾ HerbHerb** 20%20% HashHash 37%37% * Skunk-type SkunkSkunk--TypeType CannabisCannabis && PsychosisPsychosis ¾¾ComparedCompared toto HashHash smokingsmoking controlscontrols ¾¾ SkunkSkunk useuse -- 77 xx riskrisk ¾¾ DailyDaily SkunkSkunk useuse -- 1212 xx riskrisk ¾¾ DiDi FortiForti etet alal .. Br.Br. J.J. PsychiatryPsychiatry 20092009 CannabinoidsCannabinoids ¾¾ PhytoCannabinoidsPhytoCannabinoids-- onlyonly inin CannabisCannabis plantsplants ¾¾ EndocannabinoidsEndocannabinoids –– naturallynaturally occurringoccurring
    [Show full text]
  • Ergot Alkaloids As Dopamine Agonists: Comparison in Two Rodent Models
    European Journal of Pharmacology, 37 (1976) 295-302 295 © North-Holland Publishing Company, Amsterdam - Printed in The Netherlands ERGOT ALKALOIDS AS DOPAMINE AGONISTS: COMPARISON IN TWO RODENT MODELS GILL ANLEZARK, CHRIS PYCOCK and BRIAN MELDRUM Department of Neurology, Institute of Psychiatry, Denmark Hill, London, SE5 8AF, U.K. Received 18 December 1975, revised MS received 20 February 1976, accepted 26 February 1976 G. ANLEZARK, C. PYCOCK and B. MELDRUM, Ergot alkaloids as dopamine agonists: comparison in two rodent models, European J. Pharmacol. 37 (1976) 295-302. A series of ergot alkaloids, together with the DA agonists apomorphine and piribedil, were tested for protec- tive effects against audiogenic seizures in an inbred strain of mice (DBA/2) and for induction of circling behaviour in mice with unilateral destruction of one nigrostriatal DA pathway. The order of potency against audiogenic sei- zures was apomorphine> ergocornine> bromocryptine > ergometrine> LSD> methysergide > piribedil while that observed in the rotating mouse model was apomorphine> ergometrine> ergocornine> brornocryptine > piribedil. LSD caused only weak circling behaviour even when administered in high doses (> 1 mg/kg). Methyser- gide was ineffective. Prior administration of the neuroleptic agent haloperidol blocked the effect of DA agonists and of ergot alkaloids in both animal models. The possible action of ergot alkaloids as DA agonists is discussed. Ergot alkaloids Audiogenic seizures Dopamine agonists Circling behaviour 1. Introduction gic synapses, in two rodent pharmacological models. The first model studied is 'audiogen- The pharmacology of the ergot alkaloids is ic' seizures in genetically susceptible mice. complex and not well understood. Peripheral- The severity of the seizure responses to audi- ly, they act on smooth muscle as 5-hydroxy- tory stimulation can be modified by a variety tryptamine (5-HT) antagonists (Goodman and of drugs believed to act on monoaminergic Gilman, 1971) and as a-adrenergic blockers transmission in the brain (Lehmann, 1970).
    [Show full text]
  • WO 2010/099522 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 2 September 2010 (02.09.2010) WO 2010/099522 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/4164 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/4045 (2006.01) A61K 31/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2010/025725 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 1 March 2010 (01 .03.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/156,129 27 February 2009 (27.02.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, HELSINN THERAPEUTICS (U.S.), INC.
    [Show full text]
  • Risk Assessment of Argyreia Nervosa
    Risk assessment of Argyreia nervosa RIVM letter report 2019-0210 W. Chen | L. de Wit-Bos Risk assessment of Argyreia nervosa RIVM letter report 2019-0210 W. Chen | L. de Wit-Bos RIVM letter report 2019-0210 Colophon © RIVM 2020 Parts of this publication may be reproduced, provided acknowledgement is given to the: National Institute for Public Health and the Environment, and the title and year of publication are cited. DOI 10.21945/RIVM-2019-0210 W. Chen (author), RIVM L. de Wit-Bos (author), RIVM Contact: Lianne de Wit Department of Food Safety (VVH) [email protected] This investigation was performed by order of NVWA, within the framework of 9.4.46 Published by: National Institute for Public Health and the Environment, RIVM P.O. Box1 | 3720 BA Bilthoven The Netherlands www.rivm.nl/en Page 2 of 42 RIVM letter report 2019-0210 Synopsis Risk assessment of Argyreia nervosa In the Netherlands, seeds from the plant Hawaiian Baby Woodrose (Argyreia nervosa) are being sold as a so-called ‘legal high’ in smart shops and by internet retailers. The use of these seeds is unsafe. They can cause hallucinogenic effects, nausea, vomiting, elevated heart rate, elevated blood pressure, (severe) fatigue and lethargy. These health effects can occur even when the seeds are consumed at the recommended dose. This is the conclusion of a risk assessment performed by RIVM. Hawaiian Baby Woodrose seeds are sold as raw seeds or in capsules. The raw seeds can be eaten as such, or after being crushed and dissolved in liquid (generally hot water).
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • Update of the Generic Definition for Tryptamines
    ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Zahi Sulaiman 2nd Floor (NW), Seacole Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 1121 [email protected] Norman Baker MP, Minister for Crime Prevention Home Office 2 Marsham Street London SW1P 4DF 10 June 2014 Dear Minister, In December 2013, you commissioned the ACMD to begin a regular review of generic definitions under the Misuse of Drugs Act 1971, with the aim of capturing emerging new psychoactive substances. These drugs are variants of controlled drugs and fall outside the existing scope of the Misuse of Drugs Act 1971. The ACMD has considered evidence available on tryptamines in the context of the Misuse of Drugs Act 1971 and I enclose the Advisory Council’s advice and an expanded definition for tryptamine compounds with this letter. The ACMD’s NPS Committee has firstly reviewed previous research and existing controls to identify those tryptamines now seen to evade the existing controls. The ACMD has also reviewed data provided by the Home Office’s early warning systems and networks, clinical toxicology, prevalence and neuropharmacology in arriving at the expanded generic definition. This expanded generic definition will bring drugs such as alpha-methyltryptamine (AMT) as well as 5-MeO-DALT within the scope of the Misuse of Drugs Act 1971. These are highly potent hallucinogens which act on the 5HT2A receptor, in the same way as LSD. The ACMD therefore recommends that the tryptamines covered by the proposed expanded generic definition in this report, are controlled under the Misuse of Drugs Act (1971) as Class A substances.
    [Show full text]
  • Package Leaflet: Information for the Patient Dostinex® 0.5 Mg Tablets
    Package leaflet: Information for the patient Dostinex® 0.5 mg Tablets cabergoline Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Dostinex is and what it is used for 2. What you need to know before you take Dostinex 3. How to take Dostinex 4. Possible side effects 5 How to store Dostinex 6. Contents of the pack and other information 1. What Dostinex is and what it is used for - Dostinex contains the active ingredient cabergoline. This medicine belongs to a class of medicines called ‘dopamine agonists’. Dopamine is produced naturally in the body and helps to transmit messages to the brain. - Dostinex is used to stop breast milk production (lactation) soon after childbirth, stillbirth, abortion or miscarriage. It can also be used if you do not want to continue to breast-feed your baby once you have started. - Dostinex can also be used to treat other conditions caused by hormonal disturbance which can result in high levels of prolactin being produced. This includes lack of periods, infrequent and very light menstruation, periods in which ovulation does not occur and secretion of milk from your breast without breast-feeding.
    [Show full text]
  • Anesthetics; Drugs of Abuse & Withdrawal
    Anesthetics; Drugs of Abuse & Withdrawal Kurt Kleinschmidt, MD, FACEP, FACMT Professor of Emergency Medicine Section Chief and Program Director Medical Toxicology UT Southwestern Medical Center Much Thanks To… Sean M. Bryant, MD Associate Professor Cook County Hospital (Stroger) Department of Emergency Medicine Assistant Fellowship Director: Toxikon Consortium Associate Medical Director Illinois Poison Center Overview Anesthetics – Local – Inhalational – NM Blockers & Malignant Hyperthermia Drugs of Abuse (Pearls) Withdrawal History 1904-Procaine (short Duration of Action) 1925 (dibucaine) & 1928 (tetracaine) → potent, long acting 1943-lidocaine 1956-mepivacaine, 1959-prilocaine 1963-bupivacaine, 1971-etidocaine, 1996-ropivacaine Lipophili Intermediate Amine Substituents c Group Esters Structure 2 Distinct Groups 1) Amino Esters Amides 2) Amino Amides Local Anesthetics Toxic Reactions • Few & iatrogenic • Blood vessel administration or toxic dose AMIDES have largely replaced ESTERS • Increased stability • Relative absence of hypersensitivity reactions – ESTER hydrolysis = PABA (cross sensitivity) – AMIDES = Multidose preps → methylparabens • Chemically related to PABA with rare allergic reactions Local Anesthetics Mode of Action • Reversible & Predictable Binding • Within membrane-bound sodium channels of conducting tissue (cytoplasmic side of membrane) → Failure to form/propagate action potentials (Small-diam. fibersBLOCKADE carrying pain/temp sensation) Pain fibers - higher firing rate & longer AP → • ↑Sodium susceptible Channelto local
    [Show full text]
  • Phoretic Analysis of Ergot Alkaloids. Relations Mobility in the Cle Vine
    Acta Pharm, Suecica 2, 357 (1965) Thin-layer chromatographic and thin-layer electro- phoretic analysis of ergot alkaloids.Relations between structure, RM value and electrophoretic mobility in the cle vine series STIG AGUREll DepartMent of PharmacOgnosy, Kunql, Farmaceuliska Insiitutei, StockhOLM, Sweden SUMMARY A thin-layer chromatographic and electrophoretic study of the ergot alkaloids has been made, to find rapid methods for the separation and identification of the known ergot alkaloids. The mobilities of ergot alkaloids in several useful chromatographic and electrophore- tic systems are recorded. Relations have been observed between structure and R" value in methanol-chloroform on Silica Gel G. A simple, rapid thin-layer electrophoretic technique has been de- vised for separation of ergot alkaloids, and a relation between structure and electrophoretic mobility is evident. Two-dimensional combinations of thin-layer chromatography and thin-layer electro- phoresis and chromatography are described. Numerous paper chromatographic procedures have been published for separation of the ergot alkaloids and their derivatives. Hofmann (1) and Genest & Farmilio (2) have recently listed these systems. The general advantages of thin-layer chromatography (TLC) over paper partition chromatography are well known: shorter time of equilibration and devel- opment, generally better resolution, smaller amounts of substance rc- quired, and wider choice of reagents. Several reports of TLC of ergot alkaloids have been published. In gene- ral, these investigations (2-6 and others) have dealt 'with limited groups of alkaloids, or with a specific problem involving at most a dozen of the 40 now known naturally occurring ergot alkaloids. Some paper chromate- .357 graphic systems using Iorrnamide-treated papers have also been adopted for thin-layer chromatographic use (7, 8).
    [Show full text]
  • Electronic Supplementary Material (ESI) for RSC Advances. This Journal Is © the Royal Society of Chemistry 2017
    Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2017 The physicochemical properties and NMR spectra of some ergot alkaloids are summarized as following. Especially, under the influence of acids, alkaloids or light, the carbo at the position 8 of D-lysergic acid derivatives can occur isomerization which 8R is changed into 8S to form the responding isomers, lead to the formation of α-ergotaminine, ergocryptinine, ergocorninine and ergocristinine which the NMR data are shown in Table S1, S2 and S3. Clavine Agroclavine: crystal (acetone), mp 198~203℃, soluble in benzene, ethanol, slightly soluble 1 in water. Molecular formula: C16H18N2, MW m/z: 238. The data of H-NMR (Pyridine-d5,220 13 MHz) and C-NMR (Pyridine-d5,15.08 MHz) {Bach, 1974 #48}are shown in Table S1 and S2. Elymoclavine: mp 250~252℃, Molecular formula: C16H18N2O, MW m/z: 254. The data of 1 13 H-NMR (CDCl3, 220 MHz) and C-NMR (CDCl3, 15.08 MHz){Bach, 1974 #48} of its acetate derivatives are shown in Table S1 and S2. 1 Festuclavine: mp 241℃, Molecular formula: C16H18N2, MW m/z: 238. The data of H-NMR 13 (CDCl3, 220 MHz) and C-NMR (CDCl3, 15.08 MHz) {Bach, 1974 #48}are shown in Table S1 and S2. Fumigaclavine B: mp 265~267℃, Molecular formula: C16H20N2O, MW m/z: 256. The data of 1 13 H-NMR (pyridine-d5,220 MHz) and C-NMR (pyridine-d5,15.08 MHz) {Bach, 1974 #48}are shown in Table S1 and S2. Ergoamides Ergometrine: white crystal (acetone), mp 162℃.
    [Show full text]
  • Ergometrine Maleate
    The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/237/97-FINAL June 1999 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS ERGOMETRINE MALEATE SUMMARY REPORT 1. Ergometrine is a naturally occurring alkaloid found in ergot (Claviceps purpurea). It is classified as a water-soluble lysergic acid derivative, and is an orally-active stimulant of uterine contractions. The maleate salt (ergometrine maleate) exhibits greater stability than the free base and is the usual form in which the alkaloid is used in medicinal products. It is used in veterinary medicine in the control of postpartum uterine haemorrhage, removal of fluid from atonic uteri, to prevent pro-lapsed uteri, and judiciously in terms of timing to aid in suturing the uterus after caesarean section or in replacing an everted uterus. Dose regimens are: cows and mares: 2 to 5 mg/animal (intravenously or intramuscularly); ewes, goats and sows: 0.5 to 1 mg/animal (intramuscularly). In human medicine, it is used orally and parenterally in the prevention and treatment of postpartum haemorrhage caused by uterine atony and for the stimulation of uterine involution. Usual oral doses are 500 µg 3 times daily up to 1.8 mg daily (approximately 0.03 mg/kg bw). Ergot alkaloids have been reported to be present in flour from rye, wheat and barley in amounts ranging from 0.01 to 2.36 mg/kg flour. EU legislation restricts the maximum percentage of ergot tolerated in flour to 0.1%. Total daily human intake of ergot alkaloids from contaminated foodstuffs of plant origin has been estimated as up to 7.8 µg/person.
    [Show full text]